StockData

Coherus Oncology vs Pelthos Therapeutics

CHRS and PTHS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CHRS and PTHS compare

Coherus Oncology is the larger company, worth 2.9 times as much as Pelthos Therapeutics ($78.2M against $27.4M).

Pelthos Therapeutics keeps more of each dollar of sales as profit, with a net margin of −200% compared with −259% at Coherus Oncology.

Coherus Oncology scores higher on the StockData Score (7 against 2 for Pelthos Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCHRSPTHS
Size and price
Market cap$78.2M$27.4M
Share price$0.506$7.15
Change, 1 year−59.8%−79.4%
Change, 5 years−97.2%–
Beta (5Y)0.810.91
Employees14792
StockData Score
Total score7 (better)2
Valuation score3 (better)1
Growth score2 (better)0
Performance score1 (better)0
Health score11
Dividend score00
Valuation
P/S1.5×0.6× (better)
P/B1.3×–
Fair value$1.18–
Margin of safety57.0%–
Growth
Revenue growth (TTM)61.0%–
Revenue growth, 5Y average−38.4%–
Net income growth (TTM)−174%–
EPS growth, 5Y average−2.5%–
Profitability
Gross margin68.9%78.6% (better)
Operating margin−312%−133% (better)
Net margin−259%−200% (better)
Return on equity−146%–
Financial health
Interest coverage−17.5×−7.8× (better)
Current ratio1.771.98 (better)
Altman Z-score−12.31−1.83 (better)
Piotroski F-score6 (better)5
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions45.5%35.6%
Held by insiders1.3%–
Insider net buying, 12 months–$794K
Short interest, % of float8.3%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.